Editorial

November 30, 2024


Editorial for JUO 2024 Vol. 22 No. 3 - Rethinking Urologic Oncology Surgery
Cheol Kwak
J Urol Oncol. 2024;22(3):185-187.

Original Article

November 30, 2024


Early Experience of the Single-Port Robotic Transvesical Radical Prostatectomy: Case Series
Jae Hoon Chung, Hwanik Kim, Woo Jin Bang, et al.
J Urol Oncol. 2024;22(3):188-195.

Original Article

November 30, 2024


Simultaneous Prostate Target Biopsy Integrated With Radical Prostatectomy: A Pilot Study Omitting Preoperative Systematic Biopsy
Tae Young Park, Jae Young Hwang, Seong Woo Yun, et al.
J Urol Oncol. 2024;22(3):196-200.

Original Article

November 30, 2024


A Machine Learning Model for Prostate Cancer Prediction in Korean Men
Sukjung Choi, Beomgi So, Shane Oh, et al.
J Urol Oncol. 2024;22(3):201-210.

Original Article

November 30, 2024


Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Abiraterone Clinical Trials
Matthew Rashid, Eli Oldham, Griffin K. Hughes, et al.
J Urol Oncol. 2024;22(3):211-223.

Brief Report

November 30, 2024


The Current Role of Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma
Hyung Joon Kim
J Urol Oncol. 2024;22(3):224-227.

Invited Review

November 30, 2024


Exploring the Evolving Role of Metastasectomy in Advanced Renal Cell Carcinoma
Jongkyou Kwon, Sungun Bang, Kang Su Cho
J Urol Oncol. 2024;22(3):228-236.

Original Article

November 30, 2024


Clinical Application of Artificial Intelligence-Based Computed Tomography Analysis of Myosteatosis in Localized Renal Cell Carcinoma
Byeong Jin Kang, Kyung Hwan Kim, Seung Baek Hong, et al.
J Urol Oncol. 2024;22(3):237-245.

Invited Review

November 30, 2024


The Emerging Treatment of BCG (Bacillus Calmette-Guérin)-Unresponsive Non–Muscle-Invasive Bladder Cancer
Jong Ho Park, Jong Jin Oh
J Urol Oncol. 2024;22(3):246-255.

Invited Review

November 30, 2024


Trimodal Therapy in the Treatment of Muscle-Invasive Bladder Cancer
Yongsoo Jo, Hyeong Dong Yuk
J Urol Oncol. 2024;22(3):256-267.

Review Article

November 30, 2024


Artificial Intelligence: The Latest Advances in the Diagnosis of Bladder Cancer
Satyendra Singh, Ram Mohan Shukla
J Urol Oncol. 2024;22(3):268-280.

Correction

September 11, 2024


Correction: Addendum of Informed Consent Statements
J Urol Oncol. 2024;22(3):281-281.

Expression of Concern

November 30, 2024


Expression of Concern: Rare Ewingoid Dedifferentiated Liposarcoma of the Spermatic Cord Causing Testicular Artery Compression: A Case Report
J Urol Oncol. 2024;22(3):282-282.
Epidemiology of Urologic Cancer in Korea: Nationwide Trends in the Last 2 Decades
Sang Heon Han, Hyeong Dong Yuk
J Urol Oncol. 2023;21(1):32-44.

Original Article

Mar 31, 2023

The Landscape of Epidemiology in Urologic Cancers
Complex Epidemiology of Prostate Cancer in Asian Countries
Kagenori Ito, Takahiro Kimura
J Urol Oncol. 2023;21(1):5-13.

Review Article

Mar 31, 2023

The Evolving Role of Checkpoint Inhibitors in the Treatment of Urothelial Carcinoma: A Literature Review of Practice-Changing Trials
Sang Hun Song, Jong Jin Oh
J Urol Oncol. 2023;21(2):154-164.

Invited Review

Jul 31, 2023

Trimodality Therapy and Immuno-Oncology for Bladder Cancer
Prostate-Specific Antigen-Based Prostate Cancer Screening: One for All or Individualized for Each Race? – A Narrative Review
Chang Wook Jeong
J Urol Oncol. 2024;22(1):4-10.

Invited Review

Mar 31, 2024

Prostate Cancer
A Cost-Benefit Comparison of Biparametric Magnetic Resonance Imaging Versus Conventional Prostate Cancer Screening
Jung Sik Huh, Kyung Kgi Park
J Urol Oncol. 2023;21(2):121-127.

Original Article

Jul 31, 2023

mpMRI in the Management of Prostate Cancer: Role, Limitation, and Cost-Effectiveness
The Predictive Value of the Preoperative Systemic Inflammatory Response Indices in Non–Organ-Confined Disease in Upper Urinary Tract Urothelial Carcinoma
Sung Kyung Choi, Chan Hoon Gwak, Jungyo Suh, et al.
J Urol Oncol. 2023;21(2):174-180.

Original Article

Jul 31, 2023

Trimodality Therapy and Immuno-Oncology for Bladder Cancer
Prostate Imaging and Reporting and Data System Version 2.1: Limitations for Clinical Use
Byung Kwan Park
J Urol Oncol. 2023;21(2):106-111.

Invited Review

Jul 31, 2023

mpMRI in the Management of Prostate Cancer: Role, Limitation, and Cost-Effectiveness
Influence of Body Composition on the Perioperative and Survival Outcomes of Renal Cell Carcinoma
Edouard H. Nicaise, Benjamin N. Schmeusser, Yash B. Shah, et al.
J Urol Oncol. 2023;21(3):183-199.

Invited Review

Nov 30, 2023

Perioperative Considerations and Treatment for Advanced Renal Cell Carcinoma
Role of Radiotherapy in Metastatic Renal Cell Carcinomas: An Evolutionary Journey in a Misunderstood Histological Type
Chan Woo Wee, Jaeho Cho
J Urol Oncol. 2023;21(3):217-227.

Invited Review

Nov 30, 2023

Perioperative Considerations and Treatment for Advanced Renal Cell Carcinoma
Optimal Management of Bacillus Calmette-Guérin–Refractory Non–Muscle-Invasive Bladder Cancer in 2023
Jiwoong Yu, Hyun Hwan Sung
J Urol Oncol. 2023;21(3):228-240.

Invited Review

Nov 30, 2023

Optimal Management for BCG Unresponsive Non-Muscle-Invasive Bladder Cancer
Targeted Therapy Following Metastasectomy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis
Hui Mo Gu, Seung Il Jung, Dongdeuk Kwon, et al.
J Urol Oncol. 2024;22(1):34-41.

Systemic Review and Meta-analysis

Mar 31, 2024

Kidney Cancer
Global Renal Cell Carcinoma Research Trends Over 30 Years: A PRISMA-Compliant Bibliometric Analysis
Jung Hoon Kim, Ji Woong Hwang
J Urol Oncol. 2024;22(1):42-51.

Original Article

Mar 31, 2024

Kidney Cancer
The Current State and Future of Plasma Cell-Free DNA Analysis in Urologic Malignancies
Shusuke Akamatsu, Kei Mizuno, Takayuki Sumiyoshi, et al.
J Urol Oncol. 2023;21(1):23-31.

Review Article

Mar 31, 2023

Bladder Cancer in South Korea: Analysis of Trends and Risk Factors of Bladder Cancer in South Korea Using a Nationwide Database
Sangjun Yoo, Kyung-Do Han, Kwang Taek Kim, et al.
J Urol Oncol. 2023;21(1):45-52.

Original Article

Mar 31, 2023

Contemporary Management of Small Renal Masses by Urologic Oncologists: A 2022 Korean Renal Cancer Study Group Practice Pattern Survey
Joongwon Choi, Cheryn Song, Jungyo Suh, et al.
J Urol Oncol. 2023;21(1):59-69.

Original Article

Mar 31, 2023

Bladder Preservation With Transurethral Tumor Resection and Intravesical BCG Instillation in Superficial Muscle-Invasive Bladder Cancer: A 10-Year Follow-up
Dong Gyun Kim, Ji Eun Heo, Kang Su Cho, et al.
J Urol Oncol. 2023;21(1):70-78.

Original Article

Mar 31, 2023

The Prognostic Significance of Body Mass Index in Patients Undergoing Nephrectomy for Nonmetastatic Renal Cell Carcinoma
Hee Jae Yoo, Sun Il Kim, Se Joong Kim, et al.
J Urol Oncol. 2023;21(1):88-94.

Original Article

Mar 31, 2023

Korean Urologic Oncology Society Guidelines: Does Angioembolization Improve the Quality of Life for Renal Cell Carcinoma Patients With Intractable Symptoms Who Are Unfit for Surgery?
Ja Yoon Ku, Hui Mo Gu, Seong Hyeon Yu, et al.
J Urol Oncol. 2023;21(2):140-147.

Invited Review

Jul 31, 2023

Genetic Testing and Nonsurgical Management for Renal Cell Carcinoma
The Role of Magnetic Resonance Imaging (MRI) and MRI-Targeted Biopsy for Active Surveillance
Chang Wook Jeong
J Urol Oncol. 2023;21(2):97-105.

Invited Review

Jul 31, 2023

mpMRI in the Management of Prostate Cancer: Role, Limitation, and Cost-Effectiveness
Efficacy of Partial Nephrectomy in the Management of Unpredicted pT3a Renal Cell Carcinoma
Dongsu Kim, Bumjin Lim, Jungyo Suh, et al.
J Urol Oncol. 2023;21(2):148-153.

Original Article

Jul 31, 2023

Genetic Testing and Nonsurgical Management for Renal Cell Carcinoma
Impact of Multiparametric Magnetic Resonance Imaging for the Prediction of Extraprostatic Extension According to the National Comprehensive Cancer Network Risk Stratification in Prostate Cancer
Jae Hoon Kang, Jun-Koo Kang, Jae-Wook Chung, et al.
J Urol Oncol. 2023;21(2):112-120.

Topic Article

Jul 31, 2023

mpMRI in the Management of Prostate Cancer: Role, Limitation, and Cost-Effectiveness
Radical Cystectomy Versus Bladder-Preserving Therapy in Muscle-Invasive Bladder Cancer Patients After Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Retrospective Analysis
Youngheun Jo, Jun Seok Kim, Yoo Sub Shin, et al.
J Urol Oncol. 2023;21(2):165-173.

Original Article

Jul 31, 2023

Trimodality Therapy and Immuno-Oncology for Bladder Cancer
Genetic Testing for Prostate Cancer, Urothelial Cancer, and Kidney Cancer
Hyunho Han, Minyong Kang, Seok-Soo Byun, et al.
J Urol Oncol. 2023;21(2):128-139.

Invited Review

Jul 31, 2023

Genetic Testing and Nonsurgical Management for Renal Cell Carcinoma
Preoperative Renal Artery Embolization Before Radical Nephrectomy for Nonmetastatic Renal Cell Carcinoma: A Propensity Score Matched Analysis
Jin Noh, Sang Hun Song, Gyoohwan Jung, et al.
J Urol Oncol. 2023;21(3):200-207.

Topic Article

Nov 30, 2023

Perioperative Considerations and Treatment for Advanced Renal Cell Carcinoma
The Future of Adjuvant Therapy in Renal Cell Carcinoma: Recent Insights and Prospects
Hyerim Ha, Joo Han Lim
J Urol Oncol. 2023;21(3):208-216.

Invited Review

Nov 30, 2023

Perioperative Considerations and Treatment for Advanced Renal Cell Carcinoma
Clinical Outcomes of Patients With Variant Histology of Urothelial Carcinoma After Radical Cystectomy
Dan Bee Lee, Jae Yeon Kim, Yun Ha Lee, et al.
J Urol Oncol. 2023;21(3):249-256.Correction in: 2024;22(2):183

Original Article

Nov 30, 2023

Optimal Management for BCG Unresponsive Non-Muscle-Invasive Bladder Cancer
Predictive Factors of Abiraterone Response in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Jaeyoung Cho, Jungyo Suh, Dalsan You, et al.
J Urol Oncol. 2023;21(3):257-263.

Topic Article

Nov 30, 2023

Clinical Predictors of ARTA Response in Metastatic Prostate Cancer
Nonregional Lymph Node Metastasis as a Predictor of Early Progression When Using Androgen Receptor Targeting Agents in Patients With Metastatic Castration-Resistant Prostate Cancer Without Previous Chemotherapy
Sihyeon Kim, Beom Yong Rho, Dong Hyuk Kang, et al.
J Urol Oncol. 2023;21(3):264-270.

Topic Article

Nov 30, 2023

Clinical Predictors of ARTA Response in Metastatic Prostate Cancer
Negative Delta-Prostate-Specific Antigen Time Ratio as Potential New Marker of Progression-Free Survival in Castration-Resistant Prostate Cancer Patients Treated With First-Line Enzalutamide or Docetaxel
Tae Hwan Kim, Seol Ho Choo, Kang Hee Shim, et al.
J Urol Oncol. 2023;21(3):271-276.

Original Article

Nov 30, 2023

Clinical Predictors of ARTA Response in Metastatic Prostate Cancer
Early Experience With Pembrolizumab in Bacillus Calmette-Guérin Unresponsive Non–Muscle-Invasive Bladder Cancer
Chung Un Lee, Wan Song, Minyong Kang, et al.
J Urol Oncol. 2023;21(3):241-248.

Topic Article

Nov 30, 2023

Optimal Management for BCG Unresponsive Non-Muscle-Invasive Bladder Cancer

Journal of
Urologic Oncology

Print ISSN: 2951-603X
Online ISSN: 2982-7043


Editorial Office
Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine,
101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
TEL: +82-2-2072-0817,   FAX: +82-2-742-4665   Email: journal@e-juo.org
Korean Urological Oncology Society
50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: +82-2-704-8574, E-mail: leeseh@yuhs.ac

Copyright © The Korean Urological Oncology Society.

Developed in M2PI